ResMed to Celebrate 30th Anniversary & 20 Years Listed on the New York Stock Exchange by Ringing The Opening Bell® on Septem...
September 26 2019 - 9:00AM
Business Wire
ResMed (NYSE: RMD, ASX: RMD) today announced that CEO Mick
Farrell will ring The Opening Bell® at the New York Stock Exchange
(NYSE) on Monday, September 30, 2019 at 9:30 a.m. ET. Farrell will
be joined on the bell podium with other members of the ResMed
management team to celebrate 20 years of being listed on the NYSE
and to commemorate ResMed’s 30th anniversary.
Founded in 1989, ResMed began as ResCare, a management buy-out
of sleep apnea technology from Baxter Healthcare. Today, ResMed is
the world’s leading software-driven medical device company with
over 4.5 billion nights of medical sleep and respiratory care data
and over 10 million 100% cloud connectable medical devices in the
market.
“From a single A$1.25 million investment, ResMed has transformed
into a A$28 billion (US$19 billion) connected health leader,
changing over 100 million lives a year with either a
cloud-connected medical device or through software support of an
out-of-hospital care agency,” said Farrell. “I’m proud to be one of
7,500-plus ResMedians worldwide dedicated to improving the quality
of so many lives, and one of countless investors who have long seen
and supported the value of all that ResMed creates. And we are just
getting started.”
The event will be broadcast live from the NYSE and will be live
streamed online at https://www.nyse.com/bell.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions
that treat and keep people out of the hospital, empowering them to
live healthier, higher-quality lives. Our cloud-connected medical
devices transform care for people with sleep apnea, COPD and other
chronic diseases. Our comprehensive out-of-hospital software
platforms support the professionals and caregivers who help people
stay healthy in the home or care setting of their choice. By
enabling better care, we improve quality of life, reduce the impact
of chronic disease and lower costs for consumers and healthcare
systems in more than 120 countries. To learn more, visit ResMed.com
and follow @ResMed.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190926005117/en/
For investors Amy Wakeham +1 858.836.5000
investorrelations@resmed.com
For media Jayme Rubenstein +1 858.836.6798
news@resmed.com
Resmed (ASX:RMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Resmed (ASX:RMD)
Historical Stock Chart
From Apr 2023 to Apr 2024